The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world efficacy & safety of teclistamab in patients with BCMA-pretreated R/R multiple myeloma
Rachid Baz, MD, Moffitt Cancer Center, Tampa, FL, discusses a single institution study addressing the real-world safety and efficacy of teclistamab in patients with BCMA-pretreated relapsed/refractory (R/R) multiple myeloma (MM). Teclistamab was approved based on the MajesTEC-1 trial (NCT04557098); however, many patients in the clinic present with a range of high-risk features, making them ineligible for this trial. Dr Baz indicates that the efficacy of teclistamab was relatively well maintained in the real-world population when comparing the progression-free survival (PFS) and toxicity to MajesTEC-1 data; however, response rates were slightly lower. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Regeneron, Pfizer, Karyopharm, Janssen, AbbVie, BMS; Honoraria: GSK, HIKMA Cancer Network, Curio Science, AHOMPR, ASH; Membership on an entity’s Board of Directors or advisory committees: Pfizer, Janssen, BMS.
